TellBio is a development stage biotechnology company based in Beverly, Massachusetts, with the goal to revolutionize the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology and complementary therapeutics platform, TellDx and TellRx, respectively. TellBio’s vision is to free patients and their families from the tyranny of cancer via both its TellDx and TellRx platforms.

TellDx is a fully functional diagnostics solution aimed at detecting and isolating live CTCs from patient liquid biopsies. TellRx is the therapeutics platform that generates novel anti-cancer medicines by specifically targeting CTCs. The synergy of these platforms offers TellBio a unique opportunity to detect CTCs via a first-in-class, best-in-class microfluidic diagnostic platform and target CTCs with novel therapeutics to improve outcomes of patients with cancer. The TellDx platform is revenue generating and currently employed as a research tool at several centers of excellence around the world.

• Detection of viable CTCs via the TellDx platform is agnostic of the primary solid tumor
• Synergy between TellDx and TellRx platforms
• Revenue-generating biotechnology company

Intellectual Property: TellDx, TellBio’s diagnostics platform is based on unique, proprietary technology exclusively licensed from Massachusetts General Hospital

Clinical Development Plan: The TellDx platform is a fully functioning solution that is currently available for research use only (RUO) and has already been implemented at select centers of excellence around the world. TellRx, the therapeutics platform is in early-stage development and aims to generate novel therapeutics against CTCs